1-20 of 28
William Deraedt
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy of Carvykti in Cartitude-4 Versus Alternative Treatments from Daratumumab Clinical Trials for the Treatment of Patients with Lenalidomide-Refractory Multiple Myeloma

Michel Delforge, Irit Avivi Mazza, Maria- Victoria Mateos, Kristina Carlson, Keqin Qi, João Mendes, Seina Lee, Jordan M. Schecter, William Deraedt, Carolina Lonardi, Ana Slaughter, Diana Chen, Man Zhao, Kaitlyn Connors, Nitin Patel, Erika Florendo, Hermann Einsele, Binod Dhakal, Wilfried Roeloffzen
Journal: Blood
Blood (2024) 144 (Supplement 1): 7085.
https://doi.org/10.1182/blood-2024-201606
Published: 2024
Journal Articles

Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial

Noffar Bar, Roberto Mina, Anne K. Mylin, Hisayuki Yokoyama, Hila Magen, Winfried Alsdorf, Monique C. Minnema, Leyla O. Shune, Iris Isufi, Simon J Harrison, Urvi A. Shah, André De Champlain, Katharine S. Gries, Diana Chen, Quanlin Li, Tzu-Min Yeh, Ana Slaughter, Carolina Lonardi, Nina Benachour, Arnab Ghosh, William Deraedt, Martin Vogel, Nikoletta Lendvai, Nitin Patel, Octavio Costa Filho, Erika Florendo, Lionel Karlin, Katja C. Weisel
Journal: Blood
Blood (2024) 144 (Supplement 1): 2002.
https://doi.org/10.1182/blood-2024-209232
Published: 2024
Journal Articles

Patient-Reported Outcomes in the Phase 3 CARTITUDE-4 Study of Ciltacabtagene Autoleucel Vs Standard of Care in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Lines of Therapy

Roberto Mina, Anne K Mylin, Hisayuki Yokoyama, Hila Magen, Winfried Alsdorf, Monique C Minnema, Leyla Shune, Iris Isufi, Simon J. Harrison, Urvi A Shah, Jordan M. Schecter, Nikoletta Lendvai, Katharine S Gries, Eva G Katz, Ana Slaughter, Carolina Lonardi, Jane Gilbert, Quanlin Li, William Deraedt, Octavio Costa Filho, Nitin Patel, Lionel Karlin, Katja Weisel
Journal: Blood
Blood (2023) 142 (Supplement 1): 1063.
https://doi.org/10.1182/blood-2023-178798
Published: 2023
Journal Articles

Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 CARTITUDE-4 Trial

M Hasib Sidiqi, Paolo Corradini, Duncan Purtill, Hermann Einsele, Binod Dhakal, Lionel Karlin, Salomon Manier, Shinsuke Iida, Sebastian Giebel, Simon J. Harrison, Brea Lipe, Abdullah Khan, Jordan M. Schecter, Carolyn Chang Jackson, Tzu-min Yeh, Arnob Banerjee, William Deraedt, Nikoletta Lendvai, Carolina Lonardi, Ana Slaughter, Katherine Li, Diana Chen, Jane Gilbert, Tito Roccia, Man Zhao, Nitin Patel, Erika Florendo, Mythili Koneru, Octavio Costa Filho, Dong Geng, Jesus San Miguel, Kwee Yong
Journal: Blood
Blood (2023) 142 (Supplement 1): 4866.
https://doi.org/10.1182/blood-2023-178778
Published: 2023
Journal Articles

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

Clinical Trials & Observations
Adam D. Cohen, María-Victoria Mateos, Yael C. Cohen, Paula Rodriguez-Otero, Bruno Paiva, Niels W. C. J. van de Donk, Thomas Martin, Attaya Suvannasankha, Kevin C. De Braganca, Christina Corsale, Jordan M. Schecter, Helen Varsos, William Deraedt, Liwei Wang, Martin Vogel, Tito Roccia, Xiaoying Xu, Pankaj Mistry, Enrique Zudaire, Muhammad Akram, Tonia Nesheiwat, Lida Pacaud, Irit Avivi, Jesus San-Miguel
Journal: Blood
Blood (2023) 141 (3): 219–230.
https://doi.org/10.1182/blood.2022015526
Published: 2023
Includes: Supplemental data
Journal Articles

Characteristics and Outcomes in Patients with Lenalidomide-Refractory Relapsed/Refractory Multiple Myeloma Treated with 1-3 Prior Lines of Therapy: Analysis of the Individual Patient-Level Data from Daratumumab Clinical Trials

Binod Dhakal, Hermann Einsele, Jordan M Schecter, Tito Roccia, William Deraedt, Nikoletta Lendvai, Ana Slaughter, Carolina Lonardi, Kaitlyn Connors, Keqin Qi, Anil Londhe, Robin Carson, Jennifer Voelker, Patricia Cost, Satish Valluri, Erika Florendo, Lida Pacaud, Kwee Yong
Journal: Blood
Blood (2022) 140 (Supplement 1): 4320–4322.
https://doi.org/10.1182/blood-2022-159151
Published: 2022
Journal Articles

Efficacy and Safety of Cilta-Cel in Patients with Progressive Multiple Myeloma after Exposure to Non-Cellular Anti-BCMA Immunotherapy

Adam D. Cohen, María-Victoria Mateos, Yael C. Cohen, Paula Rodriguez Otero, Bruno Paiva, Niels W.C.J. Van De Donk, Thomas Martin, Attaya Suvannasankha, Christina Corsale, Jordan M. Schecter, Kevin C. De Braganca, Carolyn C. Jackson, Helen Varsos, William Deraedt, Tito Roccia, Pankaj Mistry, Xiaoying Xu, Katherine Li, Enrique Zudaire, Muhammad Akram, Lida Pacaud, Irit Avivi, Jesús San-Miguel
Journal: Blood
Blood (2022) 140 (Supplement 1): 4646–4648.
https://doi.org/10.1182/blood-2022-158563
Published: 2022
Journal Articles

DVRd Followed By Ciltacabtagene Autoleucel Versus DVRd Followed By ASCT in Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible: A Randomized Phase 3 Study ( EM agine/CARTITUDE-6)

Mario Boccadoro, Jesús San-Miguel, Kenshi Suzuki, Niels W.C.J. Van De Donk, Gordon Cook, Andrzej Jakubowiak, Deepu Madduri, Salma Afifi, An-Sofie Stevens, Jordan M. Schecter, William Deraedt, Steven Kuppens, Pankaj Mistry, Lida Pacaud, Erika Florendo, Annemiek Broijl, Francesca Gay, Roberto Mina, Leo Rasche, Philippe Moreau, María-Victoria Mateos, Hermann Einsele, Pieter Sonneveld
Journal: Blood
Blood (2022) 140 (Supplement 1): 4630–4632.
https://doi.org/10.1182/blood-2022-157021
Published: 2022
Journal Articles

Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma Not Intended for Transplant: A Randomized, Phase 3 Study (CARTITUDE-5)

Dominik Dytfeld, Binod Dhakal, Mounzer Agha, Salomon Manier, Michel Delforge, Steven Kuppens, Salma Afifi, William Deraedt, Agne Taraseviciute-Morris, Jordan M. Schecter, Jane Gilbert, Fevzi Yalniz, Erika Florendo, Lida Pacaud, Vania Hungria, Saad Z. Usmani, Maria-Victoria Mateos
Journal: Blood
Blood (2021) 138 (Supplement 1): 1835.
https://doi.org/10.1182/blood-2021-146210
Published: 2021
Journal Articles

Efficacy and Safety of Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 Subgroup Analysis

Andrzej Jakubowiak, Saad Z. Usmani, Jesus G. Berdeja, Mounzer Agha, Adam D Cohen, Parameswaran Hari, Jordan M. Schecter, Deepu Madduri, Tzu-Min Yeh, Yunsi Olyslager, Arnob Banerjee, Carolyn C. Jackson, Alicia Allred, Enrique Zudaire, William Deraedt, Changwei Zhou, Dong Geng, Lida Pacaud, Yi Lin, Thomas Martin, Sundar Jagannath
Journal: Blood
Blood (2021) 138 (Supplement 1): 3938.
https://doi.org/10.1182/blood-2021-146069
Published: 2021
Journal Articles

Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma

Thomas Martin, Saad Z. Usmani, Jesús G. Berdeja, Andrzej Jakubowiak, Mounzer Agha, Adam D Cohen, Parameswaran Hari, David Avigan, Abhinav Deol, Myo Htut, Alexander Lesokhin, Nikhil C. Munshi, Elizabeth O'Donnell, A. Keith Stewart, Jordan M. Schecter, Jenna D. Goldberg, Carolyn C. Jackson, Tzu-Min Yeh, Arnob Banerjee, Alicia Allred, Enrique Zudaire, William Deraedt, Deepu Madduri, Yunsi Olyslager, Changwei Zhou, Lida Pacaud, Yi Lin, Sundar Jagannath
Journal: Blood
Blood (2021) 138 (Supplement 1): 549.
https://doi.org/10.1182/blood-2021-146060
Published: 2021
Journal Articles

Health-Related Quality of Life in the Cartitude-1 Study of Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

Thomas Martin, III, MD, Yi Lin, MD PhD, Mounzer Agha, MD, Adam D. Cohen, MD, Myo Htut, MD, A. Keith Stewart, MBChB, Parameswaran Hari, MD MRCP, Jesus G. Berdeja, MD, Deepu Madduri, MD, Saad Z. Usmani, MDMBBS,MBA, Tzu-Min Yeh, Alicia J. Allred, PhD, Yunsi Olyslager, MSc, Arnob Banerjee, MD, Jenna D. Goldberg, MD, Jordan M. Schecter, MD, Carolyn C. Jackson, MD MPH, William Deraedt, MSc, Katharine S. Gries, PhD PharmD, John Fastenau, RPh, MPH, PhD, Xiaoling Wu, PhD, Marlene J. Carrasco, MD PhD MPH, Muhammad Akram, MD, Farah Hossain, PharmD, Andrzej Jakubowiak, MD PhD, Sundar Jagannath, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 41–42.
https://doi.org/10.1182/blood-2020-136368
Published: 2020
Journal Articles

Patient Expectations and Perceptions of Treatment in CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma

Adam D. Cohen, MD, Parameswaran Hari, MD MRCP, Myo Htut, MD, Jesus G. Berdeja, MD, Deepu Madduri, MD, Saad Z. Usmani, MDMBBS,MBA, Alicia J. Allred, PhD, Yunsi Olyslager, MSc, Arnob Banerjee, MD, Jenna D. Goldberg, MD, Jordan M. Schecter, MD, Carolyn C. Jackson, MD MPH, Katharine S. Gries, PhD PharmD, John Fastenau, RPh, MPH, PhD, William Deraedt, MSc, Marlene J. Carrasco, MD PhD MPH, Muhammad Akram, MD, Farah Hossain, PharmD, Sigrid Crawford, MA, Ross Morrison, MPH, Lynda Doward, MRes, Andrzej Jakubowiak, MD PhD, Sundar Jagannath, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 13–15.
https://doi.org/10.1182/blood-2020-136383
Published: 2020
Journal Articles

CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma

Deepu Madduri, MD, Jesus G. Berdeja, MD, Saad Z. Usmani, MDMBBS,MBA, Andrzej Jakubowiak, MD PhD, Mounzer Agha, MD, Adam D. Cohen, MD, A. Keith Stewart, MBChB, Parameswaran Hari, MD MRCP, Myo Htut, MD, Elizabeth O'Donnell, MD, Nikhil C. Munshi, MD, David E. Avigan, MD, Abhinav Deol, MD, Alexander M. Lesokhin, MD, Indrajeet Singh, PhD, Enrique Zudaire, PhD, Tzu-Min Yeh, Alicia J. Allred, PhD, Yunsi Olyslager, MSc, Arnob Banerjee, MD, Jenna D. Goldberg, MD, Jordan M. Schecter, MD, Carolyn C. Jackson, MD MPH, William Deraedt, MSc, Sen Hong Zhuang, MD PhD, Jeffrey R. Infante, MD, Dong Geng, PhD, Xiaoling Wu, PhD, Marlene J. Carrasco, MD PhD MPH, Muhammad Akram, MD, Farah Hossain, PharmD, Syed Rizvi, MD, Frank Fan, MD PhD, Sundar Jagannath, MD, Yi Lin, MD PhD, Thomas Martin, III, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–25.
https://doi.org/10.1182/blood-2020-136307
Published: 2020
Journal Articles

Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel in the Phase 1b/2 CARTITUDE-1 Study

Yi Lin, MD PhD, Thomas Martin, III, MD, Adam D. Cohen, MD, Andrzej Jakubowiak, MD PhD, Jagoda Jasielec, MD, Saad Z. Usmani, MDMBBS,MBA, Deepu Madduri, MD, Mounzer Agha, MD, A. Keith Stewart, MBChB, Indrajeet Singh, PhD, Enrique Zudaire, PhD, Tzu-Min Yeh, Alicia J. Allred, PhD, Yunsi Olyslager, MSc, Arnob Banerjee, MD, Jenna D. Goldberg, MD, Jordan M. Schecter, MD, Carolyn C. Jackson, MD MPH, William Deraedt, MSc, Dong Geng, PhD, Xiaoling Wu, PhD, Marlene J. Carrasco, MD PhD MPH, Muhammad Akram, MD, Farah Hossain, PharmD, Vickie Wang, PhD, Jesus G. Berdeja, MD, Sundar Jagannath, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-136360
Published: 2020
Journal Articles

Split First Dose Administration of Daratumumab for the Treatment of Patients with Multiple Myeloma (MM): Clinical Pharmacology and Population Pharmacokinetic (PK) Analyses

Xu Steven Xu, Philippe Moreau, Saad Z. Usmani, MD, Sagar Lonial, MD, Andrzej Jakubowiak, MD PhD, Albert Oriol, MD, Amrita Krishnan, MD, Joan Bladé, MD PhD, Melody Luo, PhD, Yu-Nien Sun, PhD, Liping Zhang, William Deraedt, Ming Qi, MD PhD, Jon Ukropec, PhD, Pamela L Clemens, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1970.
https://doi.org/10.1182/blood-2018-99-113171
Published: 2018
Journal Articles

Comparative Efficacy and Safety of Daratumumab in Combination with Bortezomib, Melphalan, and Prednisone (D-VMP) in Alcyone Versus Bortezomib, Melphalan, and Prednisone (VMP) in Vista in Newly Diagnosed Multiple Myeloma (NDMM) Patients Using Propensity Score Matching (PSM)

Michele Cavo, MD, Meletios A Dimopoulos, MD, Jesus F San-Miguel, MD PhD, Maria-Victoria Mateos, MD PhD, Andrzej Jakubowiak, MD PhD, William Deraedt, Annette Lam, Tobias Kampfenkel, MD, Ming Qi, MD PhD, Jianming He, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3550.
https://doi.org/10.1182/blood-2018-99-113128
Published: 2018
Journal Articles

Impact of Modified Dose Schedule of Bortezomib, Melphalan, and Prednisone (VMP) for Previously Untreated, Transplant-Ineligible Patients with Multiple Myeloma (MM): A Matching-Adjusted Indirect Comparison

Jesus F San-Miguel, MD PhD, Maria-Victoria Mateos, MD PhD, Hartmut Goldschmidt, MD, Pieter Sonneveld, MD PhD, Meletios A Dimopoulos, MD, Bart Heeg, PhD, Mahmoud Hashim, William Deraedt, Peter Hu, Annette Lam, Jianming He, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3553.
https://doi.org/10.1182/blood-2018-99-113157
Published: 2018
Journal Articles

Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible for Transplant (ALCYONE)

Maria-Victoria Mateos, Meletios A. Dimopoulos, Michele Cavo, MD, Kenshi Suzuki, Andrzej J. Jakubowiak, MD, Stefan Knop, MD, Chantal Doyen, MD, Paulo Lucio, Zsolt Nagy, MD PhD, Polina Kaplan, Ludek Pour, Doc,MD PhD, Mark Cook, MBChB,PhD, Sebastian Grosicki, MD PhD, Andre H Crepaldi, MD, Anna Marina Liberati, Philip Campbell, MBBS, FRACP, FRCPA, Tatiana Shelekhova, Sung-Soo Yoon, MD PhD, Genadi Iosava, Tomoaki Fujisaki, MD, Mamta Garg, MD, Christopher Chiu, PhD, Jianping Wang, Robin Carson, MD BA, Wendy Crist, BA, William Deraedt, Marie Nguyen, Ming Qi, Jesus F. San-Miguel, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): LBA-4.
https://doi.org/10.1182/blood.V130.Suppl_1.LBA-4.LBA-4
Published: 2017
Journal Articles

Daratumumab, Bortezomib, and Dexamethasone (DVd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Castor

Andrew Spencer, MD, Vania T M Hungria, MD PhD, Maria-Victoria Mateos, MD, Ajay Nooka, MDMPH, Jane Estell, Wolney G Barreto, Paolo Corradini, MD, Chang-Ki Min, MD, Eva Medvedova, MD, Piruntha Thiyagarajah, William Deraedt, Christopher Chiu, Jordan Schecter, Katja C. Weisel
Journal: Blood
Blood (2017) 130 (Supplement 1): 3145.
https://doi.org/10.1182/blood.V130.Suppl_1.3145.3145
Published: 2017